The haemodynamic effects of subcutaneous sumatriptan, a 5HT(1)-receptor agonist

被引:18
|
作者
Hood, S
Birnie, D
Hillis, S
机构
[1] UNIV GLASGOW, WESTERN INFIRM, DEPT MED & THERAPEUT, GLASGOW G11 6NT, LANARK, SCOTLAND
[2] UNIV GLASGOW, WESTERN INFIRM, DEPT CARDIOL, GLASGOW G11 6NT, LANARK, SCOTLAND
关键词
sumatriptan; 5-hydroxytryptamine; vasoconstriction; haemodynamics;
D O I
10.1111/j.1365-2125.1997.00555.x
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Aims Previous in vivo studies with sumatriptan, a 5HT(1)-receptor agonist, have demonstrated vasopressor responses in the pulmonary and systemic arterial circulation. Pulmonary artery wedge pressure (PAWP) also increases after sumatriptan injection, raising the possibility of an additional venoconstrictive action or a negative inotropic effect. The mechanism for the rise in PAWP was investigated in the study. Methods Ten patients undergoing diagnostic coronary arteriography underwent haemodynamic monitoring. Results There was a significant rise (P<0.05) in systemic and pulmonary arterial pressure and total systemic and pulmonary vascular resistance. There was a similar rise (P<0.05) in PAWP and left ventricular end diastolic pressure (LVEDP). There was no change in cardiac output nor in peak rate of left ventricular pressure rise (dP/dt). Conclusions The sumatriptan induced rise in PAWP and LVEDP appears consequent upon increased afterload although a negative inotropic effect cannot be excluded.
引用
收藏
页码:327 / 328
页数:2
相关论文
共 50 条
  • [1] EFFECT OF SUBCUTANEOUS SUMATRIPTAN, A SELECTIVE 5HT1 AGONIST, ON THE SYSTEMIC, PULMONARY, AND CORONARY CIRCULATION
    MACINTYRE, PD
    BHARGAVA, B
    HOGG, KJ
    GEMMILL, JD
    HILLIS, WS
    CIRCULATION, 1993, 87 (02) : 401 - 405
  • [2] THE EFFECTS OF ORAL SUMATRIPTAN, A 5-HT1 RECEPTOR AGONIST, ON CIRCULATING ACTH AND CORTISOL CONCENTRATIONS IN MAN
    ENTWISLE, SJ
    FOWLER, PA
    THOMAS, M
    ECKLAND, DJA
    LETTIS, S
    YORK, M
    FREEDMAN, PS
    BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 1995, 39 (04) : 389 - 395
  • [3] AGONIST ACTIVITY OF SUMATRIPTAN AND METERGOLINE AT THE HUMAN 5-HT1D-BETA RECEPTOR - FURTHER EVIDENCE FOR A ROLE OF THE 5-HT1D RECEPTOR IN THE ACTION OF SUMATRIPTAN
    MILLER, KJ
    KING, A
    DEMCHYSHYN, L
    NIZNIK, H
    TEITLER, M
    EUROPEAN JOURNAL OF PHARMACOLOGY-MOLECULAR PHARMACOLOGY SECTION, 1992, 227 (01): : 99 - 102
  • [4] THE DEVELOPMENT OF A HIGHLY SELECTIVE 5-HT(1) RECEPTOR AGONIST, SUMATRIPTAN, FOR THE TREATMENT OF MIGRAINE
    FENIUK, W
    HUMPHREY, PPA
    DRUG DEVELOPMENT RESEARCH, 1992, 26 (03) : 235 - 240
  • [5] INFLUENCE OF A SELECTIVE 5HT(1)-RECEPTOR AGONIST GR43175 ON PLATELET RESPONSIVENESS
    TOZZICIANCARELLI, MG
    DIMASSIMO, C
    TOZZI, E
    MASCIOLI, A
    DEMATTEIS, G
    CAROLEI, A
    CEPHALALGIA, 1995, 15 (06) : 472 - 476
  • [6] Influence of vascular tone on vasoconstrictor responses to the 5-HT1-like receptor agonist sumatriptan in anaesthetised rabbits
    Choppin, A
    OConnor, SE
    EUROPEAN JOURNAL OF PHARMACOLOGY, 1996, 304 (1-3) : 87 - 92
  • [7] Comparison of the vasoconstrictor effects of the selective 5-HT1D-receptor agonist L-775,606 with the mixed 5-HT1B/1D-receptor agonist sumatriptan and 5-HT in human isolated coronary artery
    Longmore, J
    Maguire, JJ
    MacLeod, A
    Street, L
    Schofield, WN
    Hill, RG
    BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 2000, 49 (02) : 126 - 131
  • [8] Sumatriptan (5-HT1D receptor agonist) does not exacerbate symptoms in obsessive compulsive disorder
    Pian, KLH
    Westerberg, HGM
    van Megen, HJGM
    den Boer, JA
    PSYCHOPHARMACOLOGY, 1998, 140 (03) : 365 - 370
  • [9] THE EFFECT OF IV SUMATRIPTAN, A SELECTIVE 5-HT1-RECEPTOR AGONIST ON CENTRAL HEMODYNAMICS AND THE CORONARY CIRCULATION
    MACINTYRE, PD
    BHARGAVA, B
    HOGG, KJ
    GEMMILL, JD
    HILLIS, WS
    BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 1992, 34 (06) : 541 - 546
  • [10] Sumatriptan (5-HT1D receptor agonist) does not exacerbate symptoms in obsessive compulsive disorder
    Kamini L. Ho Pian
    H. G. M. Westenberg
    Harold J. G. M. van Megen
    Johan A. den Boer
    Psychopharmacology, 1998, 140 : 365 - 370